Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
AbCellera will receive an upfront payment and is eligible to receive additional milestone payments
Acquisition of exclusive commercialization rights for European markets
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
The acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody
The agreement sets terms under which POC will manufacture the product or receive royalties
Subscribe To Our Newsletter & Stay Updated
